Lorina Dudkin

Statistics

Publications

Citations

763

H-Index

Active since

2001

Affiliations

St. Jude Children's Research Hospital(Current)

Nationwide Children's Hospital

Lorina Dudkin is an author at St. Jude Children's Research Hospital specializing in oncology, molecular oncology, and pharmacodynamics of anticancer agents.

Publications per year

2001–2011

Publications

Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.

Lorina Dudkin, Michael B. Dilling, Pamela J. Cheshire et al. · PubMed · 2001 · 232 citations

Medicine, Oncology, Pharmacology +17

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

Shripad V. Bhagwat, Prafulla C. Gokhale, Andrew P. Crew et al. · Molecular Cancer Therapeutics · 2011 · 201 citations

Medicine, Oncology, Pharmacology +13

The Insulin-like Growth Factor-1 Receptor–Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma

Raushan T. Kurmasheva, Lorina Dudkin, Catherine A. Billups et al. · Cancer Research · 2009 · 150 citations · Full text

Medicine, Oncology, Pharmacology +17

4E-binding Proteins, the Suppressors of Eukaryotic Initiation Factor 4E, Are Down-regulated in Cells with Acquired or Intrinsic Resistance to Rapamycin

Michael B. Dilling, Glen S. Germain, Lorina Dudkin et al. · Journal of Biological Chemistry · 2002 · 96 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report

Maryam Fouladi, Wayne L. Furman, Thomas K. Chin et al. · Journal of Clinical Oncology · 2006 · 84 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

1–5 of 5